Showing 2151-2160 of 9963 results for "".
June Issue: Melanoma Updates - Epidemiology, Diagnostics, and Treatment
https://practicaldermatology.com/issues/may-june-2025/melanoma-updates-epidemiology-diagnostics-and-treatment/35917/In this article, we review the latest changes in melanoma incidence and mortality, highlight key disparities among minority populations, and summarize emerging trends in technology and treatment that are reshaping the future of melanoma care.Part 7, 1726 nm lasers: When a patient doesn’t improve: Doctors discuss “pearls” of wisdom
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24345/Chapter 7 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about when a patient doesn’t improve: Doctors discuss “pearls” of wisdom.Advocacy and Research
https://practicaldermatology.com/series/the-practical-dermatology-podcast/advocacy-and-research/36479/The latest news and updates, plus Harrison Nguyen, MD, MBA, MPH, FAAD, discusses addressing barriers to maximizing biologics for psoriasis, and Mark Lebwohl, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to talk about some of the latest research he has been involvFDA Approval for Delgocitinib
https://practicaldermatology.com/series/c-suite-chats/fda-approval-for-delgocitinib/36650/Robert Spurr, EVP, North America for LEO Pharma, discusses the importance of an FDA-approved option for treating moderate-to-severe chronic hand eczema in adults.The Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succeVtama Approved for AD in Adults and Children
https://practicaldermatology.com/series/dermwire-tv/vtama-approved-ad-adults-and-children/30079/In this week's DermwireTV, the FDA approves Vtama (tapinarof cream 0.1%) for atopic dermatitis in adults and children; the FDA approves Nemluvio (nemolizumab) for moderate-to-severe AD; and the president of Nuance Medical discusses the acquisition of scar treatment brand, Biocorneum.Noah Worcester 2024: Dr. Bettencourt on Beach Vacations
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-bettencourt-beach-vacations/24591/Miriam Bettencourt, MD, summarizes her lecture about problems that can be encountered during beach vacations at the 2024 Noah Worcester Dermatological Society meeting.DermWire TV: Maui Derm Highlights, Plus New and Emerging Treatments for HS and Acne
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-maui-derm-highlights-plus-new-and-emerging-treatments-for-hs-and-acne/20258/In this episode of DermWire TV, we recap the biggest news from Maui Derm 2024, including safety and efficacy studies on bimekizumab, deucravacitinib, and upadacitinib. Also from Maui Derm, Raj Chovatiya, MD, PhD, highlights new therapies to treat hidradenitis suppurativa and Julie Harper, MD, highliDermWireTV: Olumiant Approved for AA; Radiesse + Launch; Derms as Influencers; VCS
https://practicaldermatology.com/topics/practice-management/dermwiretv-olumiant-approved-for-aa-radiesse-launch-derms-as-influencers-vcs/20107/Olumiant (baricitinib) from Eli Lilly and Company is approved to treat adult patients with severe alopecia areata. Dermatologists rank as top influencers of consumers’ decisions to have cosmetic procedures, according to results of the American Society for Dermatologic Surgery (ASDS) Consumer SurveyAdvocating for Dermatology: The Benefits of Being Involved
https://practicaldermatology.com/topics/practice-management/advocating-for-dermatology-the-benefits-of-being-involved/20087/Neal Bhatia, MD shares his appreciation for being able to have served as the American Academy of Dermatology’s Vice President for the last year. He shares his thoughts on the importance of getting involved and advocating for the specialty.